IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 126-150 out of 1244.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>

Public Release: 7-Dec-2014
American Society of Hematology 56th Annual Meeting
Oral inhibitor shows clinical activity in poor-prognosis AML
An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia -- a poor-prognosis group with few options -- report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center.
AbbVie, Inc.

Contact: Anne Doerr
Anne_Doerr@dfci.harvard.edu
617-632-5665
Dana-Farber Cancer Institute

Public Release: 7-Dec-2014
56th American Society of Hematology Annual Meeting
Study shows improved survival in aggressive acute myeloid leukemia
Patients who relapse in their battle with acute myeloid leukemia may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 7-Dec-2014
Journal of the National Cancer Institute
New study identifies first gene associated with familial glioma
An international consortium of researchers led by Baylor College of Medicine has identified for the first time a gene associated with familial glioma -- brain tumors that appear in two or more members of the same family -- providing new support that certain people may be genetically predisposed to the disease.

Contact: Glenna Picton
picton@bcm.edu
713-798-7973
Baylor College of Medicine

Public Release: 7-Dec-2014
56th American Society of Hematology Annual Meeting
Young adults with ALL benefit from therapies developed for children
A large, prospective clinical trial adds to mounting evidence that adolescent and young adult patients -- aged 16 to 39 with acute lymphoblastic leukemia -- fare better when treated with high-intensity pediatric protocols than previous patients treated on adult regimens.
National Institutes of Health

Contact: John Easton
john.easton@uchospitals.edu
773-795-5225
University of Chicago Medical Center

Public Release: 7-Dec-2014
56th American Society of Hematology Annual Meeting
Blood
Combination therapy shown as effective for higher-risk MDS/AML patients
A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 7-Dec-2014
56th American Society of Hematology Annual Meeting
Penn researchers announce latest results of investigational cellular therapy
The latest results of clinical trials of more than 125 patients testing a personalized cellular therapy known as CTL019 will be presented by University of Pennsylvania researchers at the 56th American Society of Hematology Annual Meeting and Exposition. Highlights of the new trial results will include a response rate of more than 90 percent among pediatric acute lymphoblastic leukemia patients, and results from the first lymphoma trials testing the approach.
National Institutes of Health, The Leukemia & Lymphoma Society's Specialized Centers of Research, Stand Up To Cancer-St. Baldrick's Pediatric Dream Team Trans

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine

Public Release: 7-Dec-2014
56th American Society of Hematology Annual Meeting
Novel combinations yield promising results for leukemia patients with poor prognoses
Recognizing that leukemia cannot be conquered with a 'one-size-fits-all' approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.

Contact: Amanda Szabo
aszabo@hematology.org
415-978-3620
American Society of Hematology

Public Release: 7-Dec-2014
56th American Society of Hematology Annual Meeting
Study shows new kind of targeted drug has promise for leukemia patients
A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial.

Contact: Andrea Baird
bairda@mskcc.org
908-307-9255
Memorial Sloan Kettering Cancer Center

Public Release: 6-Dec-2014
56th American Society of Hematology Annual Meeting
Positive study data could improve standard of care for Hodgkin lymphoma patients
In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care.

Contact: Andrea Baird
bairda@mskcc.org
908-307-9255
Memorial Sloan Kettering Cancer Center

Public Release: 6-Dec-2014
56th American Society of Hematology Annual Meeting
Benefits persist in T cell therapy for children with relapsed leukemia
An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years. The personalized cell therapy reprograms a patient's immune system and offers the potential of long-term success.

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-970-3685
Children's Hospital of Philadelphia

Public Release: 6-Dec-2014
56th American Society of Hematology Annual Meeting
New England Journal of Medicine
Immunotherapy achieves breakthrough result in patients with Hodgkin lymphoma
Eighty-seven percent of Hodgkin lymphoma patients who participated in an early-phase immunotherapy clinical trial experienced cancer remission.
Bristol Myers Squibb, National Institutes of Health, Miller Family Fund

Contact: Teresa M. Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute

Public Release: 6-Dec-2014
56th American Society of Hematology Annual Meeting
New England Journal of Medicine
Studies show immunotherapy drugs improve outcomes in Hodgkin lymphoma patients
In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. For Classical Hodgkin lymphoma patients, two phase I studies are already demonstrating dramatic results.

Contact: Andrea Baird
bairda@mskcc.org
908-307-9255
Memorial Sloan Kettering Cancer Center

Public Release: 6-Dec-2014
56th American Society of Hematology Annual Meeting
New England Journal of Medicine
Unprecedented benefit seen in test of three-drug treatment for multiple myeloma
In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination produced significantly better results than using the two drugs alone, according to a worldwide research team led by investigators from Mayo Clinic.
Onyx Pharmaceuticals Inc.

Contact: Joe Dangor
dangor.yusuf@mayo.edu
651-261-9089
Mayo Clinic

Public Release: 6-Dec-2014
56th American Society of Hematology Annual Meeting
Novel strategies direct immune system to attack recurrent, hard-to-treat blood cancers
Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

Contact: Amanda Szabo
aszabo@hematology.org
415-978-3620
American Society of Hematology

Public Release: 6-Dec-2014
56th American Society of Hematology Annual Meeting
Advances in lymphoma and multiple myeloma treatment seek to improve outcomes for patients
New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

Contact: Amanda Szabo
aszabo@hematology.org
415-978-3620
American Society of Hematology

Public Release: 6-Dec-2014
56th American Society of Hematology Annual Meeting
Circulating RNA may provide prognostic tool for multiple myeloma
The 'molecular mail' sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study being presented at the annual meeting of the American Society of Hematology by researchers at Dana-Farber Cancer Institute.
The Leukemia & Lymphoma Society

Contact: Anne Doerr
Anne_Doerr@dfci.harvard.edu
617-632-5665
Dana-Farber Cancer Institute

Public Release: 5-Dec-2014
PLOS ONE
Agent prevents prostate cancer growth and spread in animal studies
Researchers have completed a critical step in the journey from a basic science discovery in the lab to a potential clinical application by showing an experimental agent prevents tumor growth and spread in mice with prostate cancer harboring a common chromosomal abnormality. The agent, YK-4-279, is the first drug targeted at the chromosomal translocations found in about half of prostate cancer cells.
US Department of Defense

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 5-Dec-2014
American Society for Cell Biology/International Federation for Cell Biology
An unholy alliance -- Colon cancer cells in situ co-opt fibroblasts in surrounding tissue to break out
In work to be presented at the ASCB/IFCB meeting in Philadelphia, researchers from the Institut Curie in Paris report that they have evidence of a coordinated attack on the basement membrane of human colon cells by cancer cells in situ and CAF cells in the extracellular matrix that begins long before the actual translocation of cancer cells.

Contact: John Fleischman
jfleischman@fuse.net
513-706-0212
American Society for Cell Biology

Public Release: 5-Dec-2014
American Society for Cell Biology/International Federation for Cell Biology
Screening for matrix effect in leukemia subtypes could sharpen chemotherapy targeting
Jae-Won Shin and David Mooney of Harvard University's Wyss Institute for Biologically Inspired Engineering in Cambridge, MA, describe building a three-dimensional hydrogel system with tunable stiffness to see how relative stiffness of the surrounding ECM affected the resistance of human myeloid leukemias to chemotherapeutic drugs.

Contact: John Fleischman
jfleischman@ascb.org
513-706-0212
American Society for Cell Biology

Public Release: 5-Dec-2014
Proceedings of the National Academy of Sciences
IRCM researchers identify a protein that controls the 'guardian of the genome'
A new study published in the scientific journal Proceedings of the National Academy of Sciences sheds new light on a well-known mechanism required for the immune response. Researchers at the IRCM, led by Tarik Möröy, Ph.D., identified a protein that controls the activity of the p53 tumor suppressor protein known as the 'guardian of the genome.'
Canadian Institutes of Health Research, Canada Research Chairs Program, Cole Foundation

Contact: Julie Langelier
julie.langelier@ircm.qc.ca
514-987-5555
Institut de recherches cliniques de Montreal

Public Release: 5-Dec-2014
Euro Echo Imaging 2014
Austrian researchers show encapsulation of cancer drugs reduces heart damage
Austrian researchers have shown that a new technique which wraps chemotherapy drugs in a fatty cover -- called a liposome -- reduces heart damage, in a study presented today at EuroEcho-Imaging 2014.

Contact: Jacqueline Partarrieu
press@escardio.org
33-492-948-627
European Society of Cardiology

Public Release: 5-Dec-2014
Proceedings of the National Academy of Sciences
Promising compound rapidly eliminates malaria parasite
An international research collaborative has determined that a promising anti-malarial compound tricks the immune system to rapidly destroy red blood cells infected with the malaria parasite but leave healthy cells unharmed. St. Jude Children's Research Hospital scientists led the study, which appears in the current online early edition of the Proceedings of the National Academy of Sciences.
NIH/National Institutes of Allergy and Infectious Diseases, Medicines for Malaria Venture, Australian National Health

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-595-2295
St. Jude Children's Research Hospital

Public Release: 5-Dec-2014
Cell Reports
New signaling role for key protein may contribute to wound healing, tumor growth
A key protein may represent a new way to use the immune system to speed healing and counter inflammatory, infectious and autoimmune diseases, according to study led by researchers at the Icahn School of Medicine at Mount Sinai and published in the December issue of Cell Reports.
National Institute of Health, CLIP Award/Cancer Research Institute

Contact: Lucia Lee
lucia@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 4-Dec-2014
Chemistry and Biology
A poisonous cure
Take two poisonous mushrooms, and call me in the morning. While no doctor would ever write this prescription, toxic fungi may hold the secrets to tackling deadly diseases.
National Institutes of Health

Contact: Layne Cameron
layne.cameron@cabs.msu.edu
517-353-8819
Michigan State University

Public Release: 4-Dec-2014
Frontiers in Immunology
Predicting the storm: Can computer models improve stem cell transplantation?
Is the human immune system similar to the weather, a seemingly random yet dynamical system that can be modeled based on past conditions to predict future states? Scientists at VCU Massey Cancer Center's award-winning Bone Marrow Transplant Program believe it is.
NIH/National Cancer Institute

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University

Showing releases 126-150 out of 1244.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>